PMID- 36005450
OWN - NLM
STAT- MEDLINE
DCOM- 20221122
LR  - 20221203
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 152
IP  - 2
DP  - 2023 Jan 15
TI  - Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic 
      breast cancer in Australia (PeRSIA).
PG  - 267-275
LID - 10.1002/ijc.34245 [doi]
AB  - The pertuzumab study in the neoadjuvant setting for HER2+ nonmetastatic breast 
      cancer in Australia (PeRSIA-ML39622) is an analysis of safety and effectiveness 
      data from the pertuzumab patient registry. Although the prognosis of patients 
      with early stage HER2+ breast cancer has been greatly improved by advances in 
      chemotherapy approximately 25% to 30% of patients develop recurrent disease. Our 
      study aimed to examine the effectiveness of neoadjuvant pertuzumab on surgical 
      outcomes, describe the medium-term effectiveness outcomes of patients treated 
      with pertuzumab, and describe the planned and actual anticancer treatment 
      regimens that patients received. Deidentified data were collected from the 
      patients' medical records and entered into REDCap, between March 2018 and July 
      2019 (n = 95). The adverse events (AEs) reported most frequently were diarrhea 
      (20; 21.1%), rash (4; 4.2%), and LVSD (4; 4.2%; two patients during neoadjuvant 
      treatment and two patients during adjuvant treatment). AEs, >/=Grade 3 were 
      diarrhea (2; 2.1%) and LVSD (1; 1.1%). Following surgery, a breast pathological 
      complete response (bpCR) was achieved in 65 patients (70.7%; 95% CI: 60.2%-79.7%) 
      and total pathological complete response (tpCR) in 59 patients (64.1%; 95% CI: 
      53.4%-73.9%). All patients who did not achieve a tpCR obtained a partial response 
      (33/92, 35.9%). Our study is the first to capture real-world data on the use of 
      pertuzumab in the neoadjuvant setting in Australia. The effectiveness and safety 
      data are consistent with those reported in clinical trials of pertuzumab in 
      patients with HER2+ breast cancer, with no new safety concerns.
CI  - (c) 2022 UICC.
FAU - Lok, Sheau Wen
AU  - Lok SW
AUID- ORCID: 0000-0002-9919-1665
AD  - The Walter and Eliza Hall Institute of Medical Research and Peter MacCallum 
      Cancer Centre, Parkville, Victoria, Australia.
FAU - De Boer, Richard
AU  - De Boer R
AD  - Peter MacCallum Cancer Centre and St Vincent's Private Hospital, Melbourne, 
      Victoria, Australia.
FAU - Baron-Hay, Sally
AU  - Baron-Hay S
AUID- ORCID: 0000-0002-9748-1458
AD  - Royal North Shore Hospital, St Leonards, New South Wales, Australia.
FAU - Button, Peter
AU  - Button P
AD  - OzBiostats Pty. Ltd, Sydney, New South Wales, Australia.
FAU - Devitt, Bianca
AU  - Devitt B
AUID- ORCID: 0000-0002-7854-4302
AD  - Eastern Health Clinical School, Box Hill, Victoria, Australia.
FAU - Forster, Benjamin C
AU  - Forster BC
AUID- ORCID: 0000-0001-9356-8639
AD  - The Poche Centre, North Sydney, New South Wales, Australia.
AD  - Northern Clinical School, The University of Sydney, St Leonards, New South Wales, 
      Australia.
FAU - Fox, Peter
AU  - Fox P
AUID- ORCID: 0000-0002-7646-9003
AD  - Orange Health Service, New South Wales, Australia.
FAU - Harold, Michael
AU  - Harold M
AD  - The Walter and Eliza Hall Institute of Medical Research and Peter MacCallum 
      Cancer Centre, Parkville, Victoria, Australia.
FAU - Ketheeswaran, Sahisha
AU  - Ketheeswaran S
AD  - Roche Products, Pty. Limited, Sydney, New South Wales, Australia.
FAU - Kichenadasse, Ganessan
AU  - Kichenadasse G
AUID- ORCID: 0000-0001-9923-5149
AD  - Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, 
      South Australia, Australia.
FAU - Kiely, Belinda E
AU  - Kiely BE
AUID- ORCID: 0000-0002-1662-3523
AD  - Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, New South 
      Wales, Australia.
FAU - Marx, Gavin
AU  - Marx G
AD  - Sydney Adventist Hospital, New South Wales, Australia.
AD  - ANU College of Health and Medicine, The Australian National University, Canberra, 
      Australian Capital Territory, Australia.
FAU - Nott, Louise
AU  - Nott L
AUID- ORCID: 0000-0001-8646-1585
AD  - Royal Hobart Hospital, Hobart, Tasmania, Australia.
FAU - Pellegrini, Laura
AU  - Pellegrini L
AD  - Eastern Health Clinical School, Box Hill, Victoria, Australia.
FAU - Tafreshi, Ali
AU  - Tafreshi A
AD  - Wollongong Private Hospital, Wollongong, New South Wales, Australia.
FAU - Gibbs, Peter
AU  - Gibbs P
AUID- ORCID: 0000-0003-1423-4484
AD  - The Walter and Eliza Hall Institute of Medical Research and Peter MacCallum 
      Cancer Centre, Parkville, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220825
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - K16AIQ8CTM (pertuzumab)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Neoadjuvant Therapy
MH  - *Breast Neoplasms/drug therapy
MH  - Persia
MH  - Australia
MH  - Diarrhea/chemically induced
OTO - NOTNLM
OT  - HER2-positive breast cancer
OT  - anti-HER2 drugs
OT  - pertuzumab
OT  - trastuzumab
EDAT- 2022/08/26 06:00
MHDA- 2022/11/23 06:00
CRDT- 2022/08/25 08:12
PHST- 2022/06/26 00:00 [received]
PHST- 2022/07/19 00:00 [accepted]
PHST- 2022/08/26 06:00 [pubmed]
PHST- 2022/11/23 06:00 [medline]
PHST- 2022/08/25 08:12 [entrez]
AID - 10.1002/ijc.34245 [doi]
PST - ppublish
SO  - Int J Cancer. 2023 Jan 15;152(2):267-275. doi: 10.1002/ijc.34245. Epub 2022 Aug 
      25.